{"id":418155,"date":"2010-03-11T10:43:52","date_gmt":"2010-03-11T14:43:52","guid":{"rendered":"tag:www.hepatitis-central.com,2010:\/mt\/\/1.788"},"modified":"2010-03-18T13:53:58","modified_gmt":"2010-03-18T17:53:58","slug":"triple-therapy-reduces-hepatitis-c-drug-resistance","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/418155","title":{"rendered":"Triple Therapy Reduces Hepatitis C Drug Resistance"},"content":{"rendered":"<p>A review in the February 2010 issue of <em>Gastroenterology<\/em> cites viral resistance against new medications as incentive for using triple therapy to treat Hepatitis C.<\/p>\n<p>Resistance Likely to Develop With New Hepatitis C Drugs<br \/>\nAddition of drugs to interferon and ribavirin treatment improves efficacy<\/p>\n<p>THURSDAY, Feb. 25 (HealthDay News) &#8212; New drugs that block the replication of the hepatitis C virus (HCV) are likely to lead to resistance if given as monotherapy and should be given in combination with pegylated interferon and ribavirin, according to a review in the February issue of <em>Gastroenterology<\/em>.<\/p>\n<p>Continue reading this entire article:<br \/>\n<a href=\"http:\/\/www.modernmedicine.com\/modernmedicine\/Modern+Medicine+Now\/Resistance-Likely-to-Develop-With-New-Hepatitis-C-\/ArticleNewsFeed\/Article\/detail\/658994?contextCategoryId=40142\">http:\/\/www.modernmedicine.com\/modernmedicine\/Modern+Medicine+Now\/Resistance-Likely-to-Develop-With-New-Hepatitis-C-\/ArticleNewsFeed\/Article\/detail\/658994?contextCategoryId=40142<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A review in the February 2010 issue of Gastroenterology cites viral resistance against new medications as incentive for using triple therapy to treat Hepatitis C. Resistance Likely to Develop With New Hepatitis C Drugs Addition of drugs to interferon and ribavirin treatment improves efficacy THURSDAY, Feb. 25 (HealthDay News) &#8212; New drugs that block the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-418155","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/418155","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=418155"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/418155\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=418155"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=418155"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=418155"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}